Angiotensin receptor blocker-based therapy and cardiovascular events in hypertensive patients with coronary artery disease and impaired renal function

References

• Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. New Engl J Med. 2004;351: 1296–1305.
   PubMed Web of Science ®Google Scholar
• Beddhu S, Allen-Brady K, Cheung AK, Horne BD, Bair T, Muhlestein JB, . Impact of renal failure on the risk of myocardial infarction and death. Kidney Int. 2002;62: 1776–1783.
   PubMed Web of Science ®Google Scholar
• Kottgen A, Russell SD, Loehr LR, Crainiceanu CM, Rosamond WD, Chang PP, . Reduced kidney function as a risk factor for incident heart failure: The Atherosclerosis Risk in Communities (ARIC) study. J Am Soc Nephrol. 2007;18:1307–1315.
   PubMed Web of Science ®Google Scholar
• Casas JP, Chua W, Loukogeorgakis S, Vallance P, Smeeth L, Hingorani AD, . Effect of inhibitors of the renin– angiotensin system and other antihypertensive drugs on renal outcomes: Systematic review and meta-analysis. Lancet. 2005; 366:2026–2033.
   PubMed Web of Science ®Google Scholar
• Raij L. The pathophysiologic basis for blocking the rennin–angiotensin system in hypertensive patients with renal disease. Am J Hypertens. 2005;18:95S–99S.
   Web of Science ®Google Scholar
• Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, . 2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2007;28:1462–1536.
   PubMed Web of Science ®Google Scholar
• Barrios V, Escobar C, Murga N, de Pablo C, Bertomeu V, Calderón A, . Clinical profile and management of hypertensive patients with chronic ischemic heart disease and renal dysfunction attended by cardiologists in daily clinical practice. J Hypertens. 2008;26:2230–2235.
   PubMedGoogle Scholar
• Kasanuki H, Hagiwara N, Hosoda S, Sumiyoshi T, Honda T, Haze K, , for the HIJ-CREATE Investigators. Angiotensin II receptor blocker-based vs. non-angiotensin II receptor blocker-based therapy in patients with angiographically documented coronary artery disease and hypertension: The Heart Institute of Japan Candesartan Randomized Trial for Evaluation in Coronary Artery Disease (HIJ-CREATE). Eur Heart J. 2009;30:1203–1212.
   PubMed Web of Science ®Google Scholar
• Hansson L, Hedner T, Dahlöf B. Prospective randomized open blinded end-point (PROBE) study. A novel design for intervention trials. Prospective Randomized Open Blinded End-Point. Blood Press. 1992;1:113–119
   PubMedGoogle Scholar
• Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16:31–41.
   PubMed Web of Science ®Google Scholar
• Hosoda S, Kimata S, Tamura K, Nakamura M, Toshima H, Shibata J, . Follow-up of 2,733 Japanese patients with myocardial infarction. Jpn Circ J. 1995;59:121–129.
   PubMedGoogle Scholar
• Yasue H, Ogawa H, Tanaka H, Miyazaki S, Hattori R, Saito M, , on behalf of the Japanese Antiplatelets Myocardial Infarction Study (JAMIS) Investigators. Effects of aspirin and trapidil on cardiovascular events after acute myocardial infarction. Am J Cardiol. 1999;83:1308–1313.
   PubMedGoogle Scholar
• Braunwald E. Unstable angina. A classification. Circulation. 1989;80:410–414.
   PubMed Web of Science ®Google Scholar
• Gupta R, Bimbaum Y, Uretsky BF. The renal patient with coronary artery disease. Current concepts and dilemmas. J Am Coll Cardiol. 2004;44:1343–53.
   PubMedGoogle Scholar
• Hage FG, Venkataraman R, Zoghbi GJ, Perry GJ, DeMattos AM, Iskandrian AE. The scope of coronary heart disease in patients with chronic kidney disease. J Am Coll Cardiol. 2009;53:2129–2140.
   PubMed Web of Science ®Google Scholar
• Anavekar NS, McMurray JJ, Velazquez EJ, Solomon SD, Kober L, Rouleau JL, . Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N Engl J Med. 2004;351:1285–1295.
   PubMed Web of Science ®Google Scholar
• Tokmakova MP, Skali H, Kenchaiah S, Braunwald E, Rouleau JL, Packer M, . Chronic kidney disease, cardiovascular risk, and response to angiotensin-converting enzyme inhibition after myocardial infarction: The Survival And Ventricular Enlargement (SAVE) study. Circulation. 2004;110: 3667–3673.
   PubMed Web of Science ®Google Scholar
• Yamaguchi J, Kasanuki H, Ishii Y, Yagi M, Ogawa H, Fujii S, , for the HIJC Study Group. Prognostic significance of serum creatinine concentration for in-hospital mortality in patients with acute myocardial infarction who underwent successful primary percutaneous coronary intervention (from the Heart Institute of Japan Acute Myocardial Infarction [HIJAMI] registry. Am J Cardiol. 2004;93:1526–1528.
   PubMedGoogle Scholar
• Ruilope LM. Angiotensin receptor blockers: RAAS blockade and renoprotection. Curr Med Res Opin. 2008;24: 1285–1293.
   PubMed Web of Science ®Google Scholar
• The PEACE Trial Investigators. Angiotensin-converting-enzyme inhibition in stable coronary artery disease. N Engl J Med. 2004;351:2058–2068.
   PubMed Web of Science ®Google Scholar
• The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med. 2000;342:145–153.
   PubMed Web of Science ®Google Scholar
• The EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: Randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet. 2003;362:782–788.
   PubMed Web of Science ®Google Scholar
• Solomon SD, Rice MM, Jablonski KA, Jose P, Domanski M, Sabatine M, , for the Prevention of Events with ACE inhibition (PEACE) Investigators. Renal function and effectiveness of angiotensin-converting enzyme inhibitor therapy in patients with chronic stable coronary disease in the prevention of events with ACE inhibition (PEACE) Trial. Circulation. 2006;114:26–31.
   PubMed Web of Science ®Google Scholar
• Schmieder RE, Hilgers K, Schlaich MP, Schmidt BMW. Renin–angiotensin system and cardiovascular risk. Lancet. 2007;369:1208–1219.
   PubMed Web of Science ®Google Scholar
• The ONTARGET Investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358:1547–1559.
   PubMed Web of Science ®Google Scholar
• Pfeffer MA, McMurray JJ, Velazquez EJ, Rouleau JL, Køber L, Maggioni AP, , for the Valsartan in Acute Myocardial Infarction Trial Investigators. Valsartan, Captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med. 2003;349:1893–1906.
   PubMed Web of Science ®Google Scholar
• Schieffer B, Schieffer E, Hilfiker-Kleiner D, Hilfiker A, Kovanen PT, Kaartinen M, . Expression of angiotensin II and interleukin 6 in human coronary atherosclerotic plaques. Potential implications for inflammation and plaque instability. Circulation. 2000;101:1372–1378.
   PubMed Web of Science ®Google Scholar
• Neri Serneri GG, Boddi M, Modesti PA, Coppo M, Cecioni I, Toscano T, . Cardiac angiotensin II participates in coronary microvessel inflammation of unstable angina and strengthens the immunomediated component. Circ Res. 2004;94:1630–1637.
   PubMedGoogle Scholar
• Schieffer B, Luchtefeld M, Braun S, Hilfiker A, Hilfiker-Kleiner D, Drexler H. Role of NAD(P)H oxidase in angiotensin II-induced JAK/STAT signaling and cytokine induction. Circ Res. 2000;87:1195–1201.
   PubMed Web of Science ®Google Scholar
• Wassmann S, Stumpf M, Strehlow K, Schmid A, Schieffer B, Böhm M, . Interleukin-6 induces oxidative stress and endothelial dysfunction by overexpression of the angiotensin II type 1 receptor. Circ Res. 2004;94:534–541.
   PubMed Web of Science ®Google Scholar
• Schieffer B, Bünte C, Witte J, Hoeper K, Böger RH, Schwedhelm E, . Comparative effects of AT1-antagonism and angiotensin-converting enzyme inhibition on markers of inflammation and platelet aggregation in patients with coronary artery disease. J Am Coll Cardiol. 2004;44:362–368.
   PubMed Web of Science ®Google Scholar
• Ogihara T, Nakao K, Fukui T, Fukiyama K, Ueshima K, Oba K, , for the Candesartan Antihypertensive Survival Evaluation in Japan Trial Group. Effects of candesartan compared with amlodipine in hypertensive patients with high cardiovascular risks. Candesartan Antihypertensive Survival Evaluation in Japan Trial. Hypertension. 2008;51:393–398.
   PubMed Web of Science ®Google Scholar
• Ohishi M, Takagi T, Ito N, Tatara Y, Hayashi N, Shiota A, . Renal protective effect in hypertensive patients: The high doses of angiotensin II receptor blocker (HARB) study. Hypertens Res. 2007;30:1187–1192.
   PubMedGoogle Scholar